Sorich MJ - Search Results

1

Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.

Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Sullivan TR, et al. Among authors: sorich mj. Value Health. 2020 Mar;23(3):388-396. doi: 10.1016/j.jval.2019.10.015. Epub 2020 Jan 23. Value Health. 2020. PMID: 32197735 Free article.

2

The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel.

Lu CY, Karnon J, Sorich MJ. Lu CY, et al. Among authors: sorich mj. Clin Pharmacol Ther. 2011 Jul;90(1):27-9. doi: 10.1038/clpt.2011.61. Clin Pharmacol Ther. 2011. PMID: 21691272

3

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.

Sorich MJ, Horowitz JD, Sorich W, Wiese MD, Pekarsky B, Karnon JD. Sorich MJ, et al. Among authors: sorich w. Pharmacogenomics. 2013 Dec;14(16):2013-21. doi: 10.2217/pgs.13.164. Pharmacogenomics. 2013. PMID: 24279856

4

Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.

Karnon J, Edney L, Sorich M. Karnon J, et al. Aust Health Rev. 2017 Mar;41(1):1-6. doi: 10.1071/AH15122. Aust Health Rev. 2017. PMID: 26954612

5

Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.

Gray J, Sullivan T, Latimer NR, Salter A, Sorich MJ, Ward RL, Karnon J. Gray J, et al. Among authors: sorich mj. Med Decis Making. 2021 Feb;41(2):179-193. doi: 10.1177/0272989X20978958. Epub 2020 Dec 22. Med Decis Making. 2021. PMID: 33349137

6

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Rowland A, et al. Among authors: sorich mj. Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. Br J Cancer. 2015. PMID: 25989278 Free PMC article. Review.

7

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ. Rowland A, et al. Among authors: sorich mj. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31-49. doi: 10.1080/17425255.2016.1229303. Epub 2016 Sep 1. Expert Opin Drug Metab Toxicol. 2017. PMID: 27561659 Review.

8

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.

Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Sorich MJ, et al. J Thorac Oncol. 2019 Aug;14(8):1440-1446. doi: 10.1016/j.jtho.2019.04.006. Epub 2019 Apr 15. J Thorac Oncol. 2019. PMID: 30999110 Free article.

9

Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.

Hopkins AM, Rowland A, Logan JM, Sorich MJ. Hopkins AM, et al. Among authors: sorich mj. Breast. 2019 Aug;46:90-94. doi: 10.1016/j.breast.2019.05.011. Epub 2019 May 11. Breast. 2019. PMID: 31170589

10

Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.

Lim HH, Hopkins AM, Rowland A, Yuen HY, Karapetis CS, Sorich MJ. Lim HH, et al. Among authors: sorich mj. Target Oncol. 2019 Dec;14(6):743-748. doi: 10.1007/s11523-019-00683-z. Target Oncol. 2019. PMID: 31676953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

190 results

Search Page

Filters